Brief: Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
26/11/2024 12:42
Nov 26 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES SUBMITS UPDATED TESAMORELIN F8
FORMULATION
SBLA FOR FDA REVIEW
* THERATECHNOLOGIES INC - RESUBMISSION ADDRESSES FDA
CONCERNS FROM
JANUARY 2024 CRL
Source text: ID:nGNX6bCG1X
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process